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ABSTRACT 
Activation and expansion of drug reactive T 
cells are key features in drug hypersensitivity 
reactions. Drugs may interact directly with im- 
mune receptors such as the human leukocyte 
antigens (HLA) or the T-cell receptors (TCR) it- 
self, the pharmacological interaction [p-i] con- 
cept. To analyze whether the drug sulfameth- 
oxazole (SMX) interacts directly with the TCR 
and thereby contributing to signaling and T cell 
activation, we analyze two SMX specific T cell 
clones (TCC “1.3” and “H13”). Proliferation to 
SMX and 11 related sulfanilamides, Ca++ influx 
in drug stimulated T-cells and the inhibitory ef- 
fect of non-reactive sulfanilamides on SMX sti- 
mulation were analyzed. In silico docking of 
SMX and related sulfanilamide to the TCR were 
used to identify possible drug binding sites, and 
correlated to in vitro data to find the correct 
docking. In Ca++ influx assays, reactions oc- 
curred as early as 14 sec after adding SMX to 
TCC and APC. The broadly reactive clone (“H13”) 
was stimulated by 5 additional sulfanilamide, 
while one TCC (“1.3”) was reactive exclusively 
with SMX but not other sulfanilamides. Compe- 
tition experiments with sulfanilamide inhibited 
SMX induced Ca++ influx and proliferation of the 
TCC 1.3 in a dose dependent way. Docking ex- 
periments with SMX and related sulfanilamides 
confirmed and explained the in vitro data as 
docking localized binding sites for SMX and the 
5 stimulating sulfanilamides on the CDR2β do- 
main of the clone H13, while the 6 non-stimula- 
tory SA failed to bind. In TCC 1.3, SMX could be 
docked on the CDR3α of the TCR. The other, 
non-stimulatory but inhibitory SA could also be 
docked to the same site. The combined analysis 
of in vitro and in silico data show that sulfa- 
nilamide can bind directly to TCRs. It shows that 
TCR, like other receptors, appear to be reame- 
nable to manipulations by small molecules. 
 
Keywords: p-i Concept; Drug Hypersensitivity;  
Sulfamethoxazole; TCR Signaling; TCR Specificity; 
TCR-Modelling; T Cell Clones  
1. INTRODUCTION 
Sulfanilamides (SA) can elicit hypersensitivity reac- 
tions, resulting in various diseases [1,2]. A majority of 
these reactions involve the expansion of a few drug spe- 
cific T-cells, which can coordinate an inflammatory im- 
mune response resulting in a clinical picture, which often 
involves the skin [3,4]. How the immune system is 
stimulated in drug hypersensitivity reactions is still a 
matter of debate. The hapten-concept postulates that a 
small molecular compound like a drug or a drug-me- 
tabolite is too small to be immunogenic per se. If the 
small chemical forms covalent bonds to a protein, the 
hapten-carrier complex is stable and remains coupled to 
the amino acid even after intracellular processing to 
small peptides. These hapten modified peptides are im- 
monogenic when presented by the highly polymorphic 
proteins of the major histocompatibility complex (MHC), 
the so-called Human Leukocyte Antigens (HLA). The 
hapten/peptide-HLA complex can function as a neo-an- 
tigen for some T cells able to interact with it. Examples 
of haptens are penicillinG and other beta-lactam antibi- 
otics, which via their β-lactam ring can bind directly to 
lysine or serine groups within proteins. Sulfamethoxa-  
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zole (SMX) is an example for a pro-hapten, which is 
metabolized to a highly reactive SMX-NO intermediate. 
The latter binds as a hapten covalently to the sulfur of 
cysteins, however alone can also elicit immune responses 
[2,5]. Clinical effects of such reactions are heterogeneous, 
including anaphylaxis, haemolyticanaemia, or contact 
dermatitis, to name just as few [1].  
A quite different, alternative explanation for immune 
stimulations by small molecular drugs leading to hyper- 
sensitivity reactions was recently developed by our group. 
It is termed “p-i-concept”, standing for “pharmacological 
interaction with immune receptors” [6,7]. Descriptively 
it postulates that a drug may interact directly with some 
of the highly variable immune receptors, in particular 
with some of the highly polymorphic HLA-molecules 
and TCR. This is akin to drug interactions with other 
receptors, where small molecular pharmaceuticals may 
bind to an enzymatic or ligand binding site. The p-i con- 
cept does not imply the formation of stable antigenic 
hapten-carrier determinants. Neither drug metabolism 
nor protein processing is required, as the drug itself, and 
not a hapten modified peptide, is binding to the receptors. 
All interactions involved are mediated by van der Waals 
forces, salt bridges, or other electrostatic interactions 
without any direct covalent changes. Such drug-protein 
interactions are common and are mostly without func- 
tional consequences. However, some drugs may fit into 
some of these immune receptors quite stably, giving rise 
to immune stimulations [4,5]. Indeed, the chance of func- 
tionally relevant drug bindings to some immune recap- 
tors is probably related to the enormous polymorphism 
of specific immune receptors. One estimates that one 
individual harbors 109 - 1011 different T cells and distinct 
TCR based on CDR3 polymorphism, offering an enor- 
mous amount of variable binding sites [8-10]. Also the 
polymorphism of major histocompatibility complex 
(MHC)-alleles within the population is large, with pres- 
ently more than 9300 different alleles  
(http://www.ebi.ac.uk/imgt/hla/stats.html). The chance that 
some drugs may bind to a particular immune recaptor 
with a rather strong affinity is thus relatively high [10, 
11].  
One can differentiate between two forms of the p-i 
concept, and possibly more if other proteins of the im- 
munological synapse are included [12]. The labile drug 
binding to immune receptors may be stimulatory for the 
immune system by altering either the HLA-peptide- 
complex (p-i HLA) or the TCR directly (p-i TCR). The 
p-i HLA concept has been well documented in HLA as- 
sociated drug hypersensitivity reactions [13,14]. As an 
example, severe Carbamazepine hypersensitivity in Han 
Chinese occurs almost exclusively in HLA-B*15:02 
positive individuals, which has been shown to bind Car- 
bamazepine via non-covalent bonds [15,16]. Peptides 
eluted from the HLA were devoid of bound car- 
bamazepine, arguing against a haptenized carrier mole- 
cule. Similarly, the drug Abacavir binds selectively to 
HLA-B*57:01, in particular to the F-pocket of this allele. 
It may then be recognized by T-cells, which are reactive 
to this modified MHC-molecule within 60 - 300 sec, 
clearly before Abacavir uptake, metabolism and proc- 
essing could have taken place [12]. Interestingly, binding 
of Abacavir may alter the ability of HLA-B*57:01 to 
bind the usual peptides, and in the presence of Abacavir 
the MHC molecules select a modified peptide repertoire 
for presentation [17-19]. Thus, Abacavir may act as a 
peptide exchange molecule, much like invariant chains in 
HLA class II molecules, stabilizing an open or accepting 
form of the MHC [20]. The modified peptides presented 
may give rise to autoimmune or alloimmunereactions. 
A number of previous findings support the concept 
that direct drug binding to TCR (p-i TCR) may also play 
a role in drug related T cell stimulations [21,22]. Many 
drug hypersensitivity reactions were, in spite of intensive 
search, not HLA-allele restricted. Some previous inves- 
tigations with SMX and lidocain specific CD4+ T cell 
clones (TCC), generated from patients with respective 
allergies, showed that a complete T cell stimulation, as 
measured through IL-2 secretion, proliferation, and cy- 
totoxicity, required some interaction of the TCR with a 
HLA molecule, but that the allele could be exchanged 
[21-23]. Moreover, also the presented peptide could be 
exchanged [24] without affecting reactivity to SMX. 
Thus, while drug induced T cell stimulation was clearly 
HLA restricted, the involvement of a particular HLA- 
allele was not always documented, as different HLA- 
alleles (and peptides) could serve as scaffold for full 
T-cell stimulation [22-24].  
Based on these aspects, we pursued the idea that drugs 
like SMX may interact directly with the TCR, and that 
this interaction by a non-covalently bound drug can be an 
essential component of T-cell activation, as it may occur 
in drug hypersensitivity. To support this concept, we 
evaluated the stimulatory capacity of SMX and of 11 
structurally related sulfanilamides (SA) (Figure 1) with 
two SMX specific TCC, 1.3 and H13. We investigated 
the inhibitory capacity of the SMX related compounds 
for activation of TCCs by SMX itself, using proliferation 
and Ca++ influx as read out parameters. These SMX 
reactive TCR of the two TCC were sequenced and 3 di- 
mensional models were generated. Subsequently, we used 
models to check possible binding sites for SMX and 
other SA on TCR using docking software. By combining 
the in vitro and in silico generated data we could explain 
on the molecular level the stimulatory or inhibitory ac- 
tivity of SA on these two TCR.  
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Figure 1. Complete list of compounds (and abbreviations) used 
in experiments. R substituted group, inserted group shown in 
table. All R groups are connected to the sulfanilamide core, 
represented at the top by sulfamethoxazole (SMX), by a single 
bond to the N of the base sulfanilamide. 
2. RESULTS 
2.1. Differences in Proliferation of SMX  
Specific CD4+ TCC by Stimulation with 
12 Structurally Related Sulfanilamides 
The TCC generated had the CD4 phenotype, were 
MHC-DRB1*1001 restricted and reacted to concentra- 
tions of SMX between 32.5 to 250 μg/ml [4]. T cell re- 
ceptors of 7 SMX reactive TCC were sequenced (Figure 
S1). Two TCC, clones 1.3 and H13, were selected for 
further in vitro analysis, as they could be well expanded 
in vitro. TCC 1.3 proliferated exclusively with SMX, and 
was refractory to any stimulation of the 11 additional SA 
(Figure 1), although they all share the sulfanilamide core 
structure. In contrast to TCC 1.3, the TCC H13 was able 
to react to SMX, as well as to similar concentrations of 5 
related SA compounds (Figure 2). Six additional SA, 
however, did not stimulate H13 in the proliferation as- 
says. In addition to distinct cross-reactivity to different 
SA, the two TCC also differed in the strength of prolif- 
erative response, with a weaker response using TCC H13 
vs TCC 1.3 (Figures 2(A) and (B)).  
2.2. Characterizing Drug Induced Ca2+  
Influx of TCC 1.3 and H13 
According to the p-i model, the drug interacting with 
the TCR, HLA-molecule or both occurs immediately and 
independently of prior protein processing or drug me- 
tabolism. To confirm that the TCC react to SMX accord- 
ing to the p-i model, we analyzed the very rapidly ap- 
pearing elevation of intracellular Ca++ of the two TCC 
upon stimulation by SMX and the indicated panel of 
tested SA [25]. Both TCC showed a very rapid response 
with the addition of SMX. H13 reacted only if autolo- 
gous EBV-B-LCL were used as APC, while use of al- 
logeneic APC not expressing HLA-DR-B1*1001 failed 
to elicit measurable responses. In contrast, SMX induced 
stimulation of TCC 1.3 was observed with non-autolo- 
gous PBMC as well as autologous EBV lines, and also 
without adding APC, as the TCC were self-presenting 
[21]. 
In clone 1.3 the reaction was specific for SMX only. 
This SMX induced Ca++ influx was always very strong, 
similar or even higher than PHA induced influx, and 
started as early as 14 sec after addition of SMX to the 
TCC/APC cell suspension. This confirmed a p-i based 
mechanism (Figure 3(A), Figure S2(A)). Of the other 
SA, only the SA SMP gave a very moderate response, 
about one seventh of the strength of SMX, which never 
resulted in a measurable proliferation (Figure 2(A)). All 
other compounds showed no Ca2++ influx, which corre- 
lated to the proliferation data.  
Clone H13 gave a response to SMX and the 5 SA 
compounds SMT, STH, SDZ, SMR and SPD (Figure 
3(B), Figure S2(B), (C)). The same SA were stimulatory 
in the Ca++ and proliferation assays. The Ca2++ influxes 
were rapid, occurring within the first minute, again sug- 
gesting a direct p-i mechanism. Overall the H13 prolif- 
eration to SA was weaker in comparison to those pro- 
duced by SMX in clone 1.3. The compound SMD gave 
an inconsistent, weak response in Ca++ measurements, 
without proliferation, similar to the weak and inconsis-
tent response of 1.3 to SMP.  
2.3. Inhibition of SMX-Induced T Cell  
Activation by SA (TCC1.3) 
Proliferation assays with SMX and one other SA as 
competitor were conducted using a range of competitor 
concentrations. Toxicity assays were preformed first for 
all compounds, showing that most compounds started to 
become toxic above 350 ug/ml, with SMX and SMP 
having a toxicity level above 500 ug/ml before any drug 
induced cell death was observed (data not shown). 
Maximal stimulation of TCC 1.3 was reached with SMX 
at 250 ug/ml, and this was chosen as a maximum total 
drug concentration for proliferation based competition      
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(A) 
 
(B) 
Figure 2. Proliferation assays for two clones. (A) Clone 1.3 and (B) Clone H13. Each repre- 
sents the mean for 3 - 6 triplicates form different experiments. PHA (phytohaemagglutinin) 
served as positive control. Standard deviation is shown for each as bars. Solid line crossing 
Y-axis is mean of background across all experiments represented. 
 
   
(A)                                                             (B) 
Figure 3. General calcium influx for specified compounds in the TCC 1.3 and H13 (A) Clone 1.3 shows a very strong response only 
to SMX, equivalent across different experiments and stronger than PHA stimulation. (B) Clone H13. All stimulatory compounds give 
a response which was weaker compared to PHA. The unresponsive flat lines correspond to the non stimulatory compounds SMZ and 
SMP. Green arrow, indicates time of injection of each compound. 
 
assays. A minimal measurable response from SMX was 
determined to be 3 ug/ml giving a rough molar range for 
testing all competitors from 8:1 to 1:8 competitor to 
SMX. All mixtures were then tested in triplicate as 7 
combined concentrations along this range. Data was then 
used to generate an inhibition curve, reflected as a per- 
centage decrease in SMX induced proliferation (Figure 
4(A), (B) Figure S3). All compounds were found to in- 
hibit SMX induced proliferation of TCC 1.3 in a dose 
dependent manner. The inhibition ranged from 65% - 
80% at a 1:4 molar ratio of SMX to competitor. It did not 
increase with higher molar ratios significantly. In all 
cases the generated curves were indicative of a first order 
competition, showing only a single plateau, however in 5   
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(A)                                                         (B) 
 
(C)                                                         (D) 
Figure 4. Inhibition of SMX binding by other SA (TCC 1.3). (A) and (B), best and worst inhibition assay profile based on standard 
deviations (SD) generated respectively. Each represents 3 - 6 independent triplicates in standard proliferation assays across a molar 
range from 8:1 to 1:8 SMX vs. competitor compound. In 6 compounds tested the curves fit to a single site competition indicating the 
SMX and the compounds were competing for the same site. (C) Ca2++ influx inhibition for 6 SA indicated. All are at a 1:1 molar 
ratio of 125μg/ml each. One representative assay is shown from 3 independent experiments with the same results. Green arrow indi-
cates injection time of compounds. (D) Comparison of the calculated inhibition from proliferation and Ca2++ influx at 1:1 molar 
ratios, specific SA (column 1). Data are shown as % inhibition, with +/− SD, for different assay. 
 
compounds the standard deviation may cause curve fit- 
ting to miss small deviations. 
To measure an immediate response from competition 
of SA an adapted Ca2++ influx was conducted at a 1 to 1 
molar ratio of SMX to SA derivative. For this assay, the 
competitor was allowed to incubate for 5 minutes with 
the T cell 1.3 and APC, prior to addition of SMX. With- 
out pre-incubation, no consistent inhibition was observed. 
Our adapted protocol allowed the inhibition calculated 
for each compound to remain the same, and no difference 
was observed for calculated inhibition with increased 
incubation times (data not shown). Influx assays were 
then generated for each SA against SMX, giving de- 
creased Ca2++ influx with all compounds tested (Figure 
4(C), Figure S4). Comparison of calculated inhibition 
for each compound matched well with those generated 
by proliferation assays alone in 6 SA derivatives, but  
varied slightly for the remaining compounds (Figure 
4(D)). The immediate inhibition of Ca2++ influx by all 
compounds according to the protocol used indicates the 
reaction kinetics related to the SA binding to the TCR are 
under 5 minutes. 
No inhibition was observed for H13: addition of non- 
stimulatory compounds did not affect the proliferation, 
addition of stimulatory compounds to low SMX concen- 
trations dose dependently enhanced the proliferation. 
Data not shown.  
2.4. Generation of 3D TCR Models and SA 
Docking 
Models were generated for each of the TCR indicated 
(Figure S1), as described in methods. In addition, 4 
models for non-SMX specific human TCR and a mouse 
TCR were also generated as controls. Small molecule 3D 
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structures were generated for SMX and each of the SA 
using chemsketch software and openbabbel to generate 
3D coordinates in PDB format. Each small molecule was 
then docked several times against the individual TCR 
models globally. Various common binding sites were 
found across all TCR, including the mouse model (Fig- 
ure 5). These sites may not be functionally relevant, as 
they occurred in all TCR models including non-SMX 
specific TCR and the mouse TCR. The access to some of  
 
 
(A) 
 
(B) 
Figure 5. Global Docking of sulfanila- 
mides. (A) TCR from clone H13 (B) TCR 
from clone 1.3. Shown are clustered SMX 
at a common site between the Vα and Vβ 
domains of the TCRs. The secondary clus- 
ters at the CDR2β and CDR3α are shown 
in A and B respectively. A random SMX 
docking conformation is also shown in A, 
below the invariant domain, to illustrate 
random affinities for SMX around the TCR, 
due to the highly reactive sulfate in SMX. 
these sites appears to be blocked by other proteins, such 
as CD3 subunits and glycosylation [26,27]. Of interest 
were the additional binding sites on the CDR3α and 
CDR2β loops, which were found exclusively on the 
SMX reactive TCR H13 and TCR 1.3. 
2.5. Docking of SA to the TCR of Clone H13 
The TCC H13 and H25 proliferated to SMX and 
showed docking of SMX to the CDR2β loop of TCR 
H13 and H25. Clone H13 was chosen for a more detailed 
analysis at the molecular level. Using a refined approach, 
where parameters were set to encompass the CDR2β 
loop alone, it was found all compounds tested could be 
made to dock around the suspected site of activity (Fig- 
ure 6(A), (B)). The SA core of the reactive compounds 
SMX, SMT, STH, SDZ, SMR, SPD formed interactions 
with SER 54, TYR 58, LEU 68 and ASN70 of the 
CDR2β loop. In addition, residues LYS 64 and ASP 65 
seemed necessary to make up the overall pocket visible 
on the CDR2β, along with ASP 65 forming a salt bridge 
with the sulfur of the SA core itself at 3.8 Å. Two other 
hydrogen bonds were formed with atoms in the backbone, 
ALA 56 and THR 57 respectively, which could also be 
accommodated with amino acid substitutions not causing 
steric hindrance with the SA R-groups, as the interactions 
were with backbone atoms alone. In addition, hydropho- 
bic interactions also played a role, by providing an in- 
ward force for the R-groups from the amino acids ALA 
56, THR 57 methyl group, LEU 68 and to a limited 
amount ILE 69. Together, these later 4 amino acids make 
up a hydrophobic region in one half of the CDR2β 
pocket itself. The strongest interaction was with an oxy- 
gen of the SO2 group of the SA core and the terminal 
OH of TYR 58 which seemed indispensable for the in- 
teraction. 
In non-stimulatory compounds (SID, SMZ, SMP, 
SDM, SMD, SDX), the R substituted group size alone 
prevented the SO2 and NH2 groups from being properly 
positioned in the CDR2β binding pocket. This was by 
preventing the proper distance between the TYR 58 SA 
SO2, where no hydrogen bonding could occur (Figure 
6(C), (D)). From superposition of conformations, it was 
observed that this TYR alone oriented the reactive SA 
into a tightly bound position. The respective R groups 
had a small but apparent degree of flexibility in the op- 
posite side of the whole binding pocket. Using flexible 
docking the non-reactive compounds could dock their R 
groups into the later site in differing conformations, 
moving LEU 68 aside by 1 Å. However none could 
properly place the terminal NH2 or SO2 core of the SA 
in the same orientation as the reactive compounds simul- 
taneously. This was due to steric hindrance from the lar- 
ger R groups, moving the SO2 and NH2 away from the 
loop by only 2 - 3 Å when bound at one end. A fixed  
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Figure 6. Docking of SA to the CDR2β loop of clone H13. (A) SMX bound in a pocket formed 
by the residues indicated. 6 hydrogen bonds are shown as yellow dashes, with distances in Å. 
An additional salt bridge with the SMX sulfur and ASP 65 (top right) occurs at 3.8 Å. (B) The 
stimulatory SA SMR (aqua) and the non stimulatory SA SDM (green) overlaid with SMX blue. 
The SA core of SMR and SMX align with less than 0.01 Å difference, while SDM cannot place 
the domain properly due to steric hindrance from the R group. (C) Surface map with atomic ra-
dii colored as nitrogen blue, oxygen red and all other atoms white. SDM white, SMR aqua and 
SMX blue in the same orientation as in (B) to illustrate the shape of the loop and resulting 
pocket. (D) same as (C) rotated 90˚ clockwise to show the depth of the pocket. 
 
angle with the N to S-C bond in the SA core, which has a 
range 110.0˚ +/− 2.5 in either direction, was the primary 
cause [28,29].  
Overall in clone H13, SMX was able to form 6 hy- 
drogen bonds and 1 salt bridge bound within the pocket. 
After energy minimization, these bonds were, SMX to 
residue respectively, O of SO2 to TYR 58 terminal H 2.7 
Å, O of SO2 to LEU 68 Methyl H 2.8 Å, H of terminal 
NH2 to ASN 70 terminal N 3.2 Å, H of terminal NH2 to 
SER 54 terminal O 3.1 Å, N ring to ALA 56 NH back- 
bone 1.9 Å, O ring to THR 57 NH backbone 2.9 Å. A 
single salt bridge is accommodated by ASP 65 terminal 
O and the sulfur of the SMX at 3.8 Å. Additional weak 
interactions with the SA core benzyl ring are re-enforced 
by LEU 68, and a few weak interactions between LYS 64 
terminal NH3 and the pentameric ring carbons of the 
SMX R group. These ring carbons have a weak negative 
charge of 0.06 eV due to the cyclic effect of the specific 
R group, far lower than a hydrogen bond strength but 
measurable. The other docked compounds which gave a 
response in the Ca2++ and proliferation assays maintain 
all the SA core hydrogen bonding, with differences re- 
spective to the R substituted groups.  
For H13, dehydrated SA showed a much wider degree 
of docking affinities. By removing the indicated hydro- 
gen alone, it was possible to find an orientation in which 
all SO2 groups could form a bond with the TYR 58. The 
overall orientations placed the SA core within or 1 - 2 Å 
displaced from the SER 54 and ASN 70 site. Main dif- 
ferences were a change in the S-N-C angle from 110˚ to 
127˚+/− 2, and the nitrogen charge from almost neutral 
to −0.4, simply from removing the hydrogen (Supple- 
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mental Figure 5(B)). 
2.6. Docking of SA to the TCR 1.3 
Using affinity of 6.5 kCal/mol cutoff for positive ver- 
sus negative docked conformations and as second crite- 
rion the involvement of at least 5 hydrogen bonds for 
each compound, the stimulatory SMX and all other 11 
non-stimulatory sulfanilamides were found to dock into 
the CDR3α loopof clone 1.3. This is compatible with the 
ability of all 11 SA to block SMX stimulation in func- 
tional assays and suggests that competition of SA with 
SMX for the same binding site accounts for the blocking 
effect observed in Ca2++ responses, or proliferative ca- 
pacity. All SA showed a range of between 5-7 hydrogen 
bonds per compound and direct hydrophobic interactions 
with PHE 92 of the CDR3α loop. A pi orbital interaction 
occurred with SMP and SMX in orientations where the 
SA core unit points to the peptide groove (Figure 7(A)). 
For all compounds which bound with the SA core ori- 
ented away from the peptide groove of the MHC, LEU 
99 also provided a hydrophobic interaction for the cyclic 
portion of the SA core. An energy minimized overlay of 
all compounds was then conducted to compare differ- 
ences in binding (Figure S6). All 10 other SA were not 
able to bind in this reversed orientation, as the size for R 
groups of the SA derivatives were too large to fit in, or 
due to charge as described below. This second conforma- 
tion adopted by all compounds is illustrated (Figure 
7(B)), showing the R groups oriented towards the MHC- 
peptide groove. Overall, two oxygens of the SA SO2 
were able to form hydrogen bonds with loop backbone 
NH. Additional amino specific interactions with the NH 
of the SA S-N-R neck (Figure 1), along with the O of the 
SO2 were observed with GLY 95 H and ASN 91 NH2 
respectively. In non-reactive SA the NH2 groups of the 
SA core were always positioned inwards forming a hy- 
drogen bond with the CDR1β TYR 31 (Figure 6(B)). 
Further docking was conducted in a refined set of di- 
mensions only including the CDR3α loop, yielding the 
same results.  
There is also an effect observable between the hydro- 
phobic groups of the CDR3 loop, which hinder the re- 
versed orientation for a limited set of compounds. This is 
apparent by looking at SMP and SMD which differ in 
only one additional charge (Figure 1). SMP has a com- 
plete benzene like hydrophobic side to the R group, 
while SMD has a nitrogen with a large negative charge 
of 0.4 to 0.5 due to the cyclic nature of the ring. This 
nitrogen would interact with the loop rather than passing 
through until the SO2 core is recognized. SMP is able to 
use hydrophobic interactions with THR 97 and LEU 99 
to push the R group through into an opposite orientation. 
Docking of all compounds in a dehydrated form (Sup- 
plemental Figure 5(A)) only lowered overall docking  
 
Figure 7. Docking to energy minimized TCR 
model generated from the sequenced clone 1.3 
TCR. (A) Shows SMX bound in the CDR3α 
loop in a reversed conformation, where the SA 
NH2 is oriented towards the peptide of the 
MHC peptide groove. (B) SID, brown and 
SMD fuchsia, all SA compounds except SMX 
and SMP, can bind only in the second confor- 
mation. A difference in TYR 31 is shown, as 
the TYR 31 anchors the compounds via direct 
hydrogen bonding with the SA core NH2, only 
via this conformation. In SMX, and SMP there 
is direct interaction from the R group with 
backbone N or O, as well as a single hydrogen 
bond to GLY 95 H. 
 
affinities, mostly by disruption of the PHE 92 hydropho- 
bic interaction, and slight movement of the SO2. In the 
non-dehydrated SA the SO2 was always oriented in the 
CDR3α loop center with a repulsive effect from the hy- 
drogen of the SA neck from loop backbone oxygens and 
positive NH backbone atoms (Figure S5(A)). Dehydrat- 
ing the SA adds an additional negative charge in this in- 
teraction. Loop residue ASN 91 made up a net difference 
for loss of 1 O to NH interaction by moving hydrogens 
towards one O of the SO2. This shows computationally 
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the SA SO2 core is the primary recognized portion of the 
molecule by the CDR3α loop. 
2.7. Further T Cell Clone and TCR  
Characteristics 
The two TCC analyzed were CD4+, expressed the skin 
homing receptor CCR4 but not CCR10, were perforin 
positive and expressed CD107a upon activation by SMX 
(Figure S7). For clone 1.3 the CD107a upregulation is 
maximal at 2 hours post stimulation with SMX. Inhibi- 
tion of this up-regulation of surface expressed CD107a 
was observed using STH for clone 1.3 (Figure S7(C)). 
At approximately a 1 to 1 molar ratio STH was able to 
diminish degranulation in clone 1.3 by 50% at 2 hours. 
Overall, the competition may have only delayed the 
up-regulation, as time points at 4 hours indicated a slight 
increase in CD107a with STH/SMX induction indicating 
either a prolonged competitive binding and lower induc- 
tion, or only lower initial stimulation. 
3. DISCUSSION 
In this study we pursued the concept of direct drug in-
teractions with immune receptors. We used the model of 
SMX hypersensitivity and respective TCC to analyze a 
stimulatory potential of direct SA binding to certain TCR. 
We took advantage on previous studies of SMX specific 
TCC, which had already revealed their dependence on 
APC for optimal stimulations and that different TCC, 
with structurally different TCR, show quite distinct 
cross-reactivities with up to 11 additional SA [4,30]. In 
this study we focused on two distinct TCR/TCC (1.3 and 
H13), which showed distinct cross-reactivities to 11 SA 
and correlated their functional, structural, and inhibitory 
in vitro data with computational docking data. This com-
bined analysis allowed to locate the SMX binding site to 
either the CDR3α for 1.3 and to CDR2β for H13 and to 
explain the different functional and inhibitory capacities 
of the SA on the two TCR/TCC 1.3 and H131.  
The TCC used are characterized as “p-i-clones”, 
meaning that their stimulation was not dependent on 
prior drug metabolism and presentation of a SMX- 
modified peptide by APC. Such p-i interactions of drugs 
are often very labile, and washing the cells,T-cells, APC 
or both, already abrogates reactivity [5]. The only excep- 
tion with rather stable binding is Abacavir [13,17], as this 
compound has been shown to bind with sufficient affin- 
ity to the HLA-B*57:01 molecule without being re- 
moved by washing. This lability of drug binding to im- 
mune receptors make it difficult to analyze the p-i con- 
cept by biochemical means or use e.g. of radioactive la- 
beled drugs, as these methods all require washing steps. 
Both TCC showed a rapid Ca++ influx after adding 
the compounds to TCC in the presence of APC. This 
immediate reactivity for both clones was even faster 
thanthe TCC reactivity of high affinity abacavir reactive 
TCC, which reacted after ca. 60 - 100 sec [13]. This 
rapid Ca++ influx is similar to other drug-receptor inter- 
actions, where signaling occurs within seconds rather 
than hours for non-channel based receptors. We opted to 
perform the analysis with TCC instead of transfected cell 
lines, as the reactivity of TCC was substantially higher. 
All assays were done with non-toxic concentrations, 
mostly with 250 μg/ml of SMX or related SA. 
While both TCC reacted rapidly to SMX with imme- 
diate Ca++ influx, the two TCC H13 and 1.3, are quite 
different if analyzed in detail. As reported previously, 
using TCR transfected cell lines, which are devoid of self 
HLA-molecules, full activation by SMX, reflected as 
IL-2 secretion or proliferation, required not only the 
presence of the drug, but also an interaction with HLA- 
molecules on APC [23,31,32]. In the case of TCC H13 
the HLA-DR-B1*1001 molecule, provided by autolo- 
gous EBV transformed B cells alone, was a requisite. In 
contrast, the TCC 1.3 reacted to SMX regardless of 
PBMC type used, as it was self-presenting.  
A clue to an in depth analysis of the two TCC was 
their different reactivity to 11 other SA. Their responses 
in the T-cell assays were only due to cross-reactivity of 
the originally SMX specific TCC, and not due to prior 
exposure to the SA, which are mostly not available as 
drugs or only for veterinary use. TCC 1.3 proliferated 
only to SMX, while the other 11 SA were not stimulatory, 
even if their molecular structure was rather similar (Fig- 
ure 1). Ca++ influx measurements confirmed the exclu- 
sive SMX reactivity, with the exception of the SA SMP, 
which stimulated a minor Ca++ influx, but no prolifera- 
tion. Interestingly, all non-stimulatory SA did inhibit the 
proliferation or the Ca++ influx to SMX stimulation in 
TCC 1.3. In the proliferation assays, the inhibition was 
maximal with ~50% - 70% at a 4:1 ratio of SA/SMX. 
The inhibitory effect was dose dependent and achieved at 
non-toxic concentrations of SMX and competing com- 
pounds together. Ca++ influx was also inhibited, but only 
if the blocking SA was added 5min before SMX. The 
inhibition was averaging 27% - 37%, and consistent with 
that calculated by proliferation inhibition curves at the 
same SA/SMX ratio.  
The TCC H13 reacted with SMX and 5 additional SA, 
while 6 other SA failed to stimulate this TCC. The 
non-stimulatory compounds did not inhibit SMX reactiv- 
ity in competition assays, because their intrinsic stimula- 
tory activity was very similar to the stimulatory activity 
of SMX. Thus, the stimulatory compounds increased the 
1The SMX binding site on H13 were further analysed using functional 
dynamics (St. Watkins and WJ Pichler: Sulfamethoxazole Induces a 
Switch Mechanism in T cell Receptors Containing TCRVβ20-1 by 
Altering pHLA Recognition, PLOS one, submitted. 
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effect of SMX in a dose dependent way (data not 
shown). 
As drug and HLA interactions seem to be involved in 
full T cell stimulation, it is possible that SMX and the 
other SA bind first to the HLA, and are then recognized 
by the TCR. However, our data argue strongly against 
first HLA-binding (actually HLA-DR-B1*1001). All SA 
and SMX have shown some functional involvement, 
either stimulatory or blocking, and these differences 
cannot be explained by DR-B1*10:01 binding, which is 
not different between TCC 1.3and H13. E.g., the SA 
STH stimulates H13, but does not stimulate 1.3:If this 
would be explained by binding to HLA-DR-B1*1001, 
one has to postulate that STH has no binding sites on the 
TCR 1.3, while the TCR H13 binds STH. But STH was 
able to block SMX (1.3), and could stimulate (H13). Or 
the SA STH andSMTare both able to block the SMX 
induced stimulation of TCC 1.3. However the reaction of 
H13 to SMX is not blocked, and STH and SMT are ei-
ther stimulatory (STH) or gives no response (SMT), a 
constellation which is not compatible with the hypothesis 
that both SA would compete with SMX binding on 
HLA-DR-B1*1001. Therefore, the reactivity of compet-
ing SA differs depending on the TCR, not on the HLA 
site, which is identical for both TCC. 
[31,32] To explain the differences in the reactivity of 
H13 and 1.3 to SMX and related SA as well as to under- 
stand the differences in blocking SMX induced stimula- 
tion by SA we applied docking models for the SA and 
TCR. Initial SMX docking experiments showed that 
SMX and other SA might bind to a number of sites on 
the whole TCR. All of these global binding sites are out- 
side the antigen-specific interaction site facing the MHC- 
peptide complex, and whether they are accessible to 
drugs is unclear. It is likely that these possible dockings 
occur via the sulfur moiety in the SA, which can form 
non-covalent interactions with a multitude of amino ac- 
ids on protein surfaces without a functional consequence, 
as non-specific binding of this type has been shown to 
occur with similar compounds. 
Docking revealed two unique sites on either TCC H13 
or 1.3, characterized by 5 - 7 hydrogen bonds, which 
were absent on the TCR without SMX specificity. They 
were identified on the CDR2β of TCR H13 and on 
CDR3α of TCR 1.3. How can one be sure that these sites 
are relevant? As we used TCC instead of TCR trans- 
fected cell lines, which had a better discriminatory power 
than TCR transfected cell lines, we took the approach to 
use distinct SA to define the possible binding site. This 
proved to give rather clear results, and helped discrimi- 
nate HLA or TCR interactions. The CDR2β binding site 
for SMX on the H13 TCR was capable of binding the 5 
additional stimulatory SA, while the 6 non-stimulatory 
SA did not bind. Thus, the docking data were in agree- 
ment with the functional data and could thus explain the 
selective stimulation by SMX and the 5 SA.  
With TCR 1.3, docking revealed 7 hydrogen bonds to 
SMX on the CDR3α region, with almost an antibody like 
recognition of the compound [33]. The other 11 non- 
stimulatory SA were also binding to this site, with an 
equal affinity. This overlap in binding sites could explain 
the blocking effect of the 11 SA on SMX induced prolif- 
eration and on Ca++ influx. However, it did not explain 
why SMX was stimulatory, while the other SA were not. 
A closer look at SMX and SA binding in TCC 1.3 re- 
vealed subtle, but possible relevant differences. Overall 
only two compounds were eliciting a measurable Ca2++ 
response, while the rest of SA did not. Both Ca2++ in- 
flux inducing SA, SMX and SMP, were the only SA able 
to bind in two orientations to the CDR3α loop. All the 
non-stimulatory SA contained an R groups, which pre- 
vented an orientation, where the terminal NH2 of the SA 
core was oriented towards the peptide groove. Thus 
SMX and SMP might be stimulatory in Ca2++ influx, 
because they were the only compounds able to interact 
with the TCR differently than the other SA. Why only 
SMX induces proliferation needs to be evaluated further.  
For clone H13 two separate characteristics of the 
compounds and their ability to bind in specific orienta- 
tions seem to be important, which may also shed light on 
more detailed functioning of the TCR at the amino acid 
level. In the 6 non-stimulatory SA (SID, SMZ, SMP, 
SDM, SMD, and SDX), the size of the R group hinders 
the SA core to positioning itself in the orientation de- 
picted in Figure 6(A). The overall distance of the SO2 of 
these non-stimulatory SA is moved from the pocket by 
only 1 - 2 Å. This small shift moves an O of the SO2 
away from a proper orientation against the TYR 58, 
which seems to be indispensable in anchoring the SA 
core within the loop. Interaction with TYR 58 has been 
postulated as important on MHC class 1 TCR interac- 
tions via mutational studies, as well as invariant chain 
TCR T cells [32-35]. Another aspect was that the termi- 
nal NH2 of the SA cannot be properly placed, if the an- 
gle of the S-N-R in the SA is not correctly bent. Our 
computational results show that by modeling similar 
structures and their angles in this neck region, changing 
the bend from 110˚ to 127˚ allows all compounds to dock 
into this site. Respective R groups bind in the end portion 
above THR 57 (Figure 6(C), (D)), for all SA but fail to 
be able to simultaneously place the SA core in the other 
end of the pocket. Thus, size of the R group and angle of 
the S-N-R influence the ability to bind to H13.  
Our data suggest that drugs like SMX and other SA 
may interact directly with TCRs and that they can induce 
T cell activation if an additional interaction with the 
HLA molecule is provided [23,30]. Actually, the SMX 
binding may alter the interaction of the TCR with pMHC, 
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as shown by computational analysis of TCR H13§. The 
drug binding has to occur at certain, functionally relevant 
sites of the TCR, such as the CDR3 or CDR2 sites. 
Structurally related molecules may also bind: they may 
signal as well, or may just bind, without signaling, or 
may block signaling of a competing SA. This means that 
computational studies may reveal a possible binding site, 
but must be followed by functional analysis, as drug 
binding does not necessarily lead to signal transmission.  
The consequences of these findings are multifold. 
With regard to drug hypersensitivity, the starting point of 
our investigations, our data underline the p-i concept and 
their two subforms. In one model, p-i (HLA), drugs 
preferentially interact with certain HLA molecules [13, 
17-19]. These reactions are exemplified by strong HLA- 
allele restricted hypersensitivity reactions. Immune 
stimulation in this model occurs by the reactive T cell, 
which itself is not altered by the drug, but possesses a 
TCR able to interact with the MHC-drug-peptide com- 
plex. As shown in the carbamazepine model, only if such 
T-cells are present in the circulation, the carbamazepine- 
MHC complex is harmful [36] In the abacavir model, all 
individuals possess reactive TCC/TCR, which recognize 
the abacavir-MHC-peptide complex [12] or altered pep- 
tides [17-19]. It is a more indirect stimulation of T cells.  
In the p-i (TCR) model, an initial interaction of the 
drug with a peculiar TCR occurs.It is a more direct effect 
of the drug on the reactive cell, the T cell. The details of 
the drug induced TCR signaling are not yet clear: The 
MHC/peptide may act as scaffold and/or the SMX bind- 
ing to TCR may result in some change of the TCR which 
results in better binding to pMHC§. 
The immunological consequences of our data are also 
multifold. The data illustrate that the drug binding re- 
gions of the TCR show an extreme fine specificity and 
fine tuning for signaling. Our findings may provide fur- 
ther tools to decipher this still enigmatic area of TCR 
signaling and specificity. These studies also show that 
TCR-MHC interactions might be amenable to usual 
pharmacological tools like blocking of a receptor by a 
competing ligand.  
The p-i TCR concept implies that the T cell stimulated 
by a drug in adverse reactions also have a peptide speci- 
ficity, which is mostly unknown. Preliminary data with 
allo- and simultaneously drug reactive T cells have in- 
deed revealed that an allo-reactivity can be blocked by a 
drug (unpublished). As the data always refer to only one 
single TCC/TCR, and another TCC behaves differently, a 
therapeutic intervention (e.g. blocking a certain TCR) 
could be imagined only on clonal expansions, since other 
TCC would react differently to the same drug. An exam- 
ple is the SA STH: it is inhibitory for SMX stimulation 
by TCC 1.3, but the same SA further enhances the SMX 
triggered stimulation of H13, which comes from the 
same individual.  
In conclusion, drug hypersensitivity reactions may not 
only develop because drugs are binding to HLA but also 
on drug binding to TCR. These are highly interesting 
models for “unusual” T cell stimulations and may open 
new possibilities of pharmacological interventions with 
the specific immune system. In addition, drug interac- 
tions may prove a means to further understand function- 
ality of immune receptors.  
4. MATERIALS AND METHODS 
4.1. T Cell Clones 
The PBMC, EBV B cell lines and T cells were derived 
from a patient with exanthema, malaise and well docu- 
mented SMX specific T cell proliferation in vitro [4,37]. 
Cloning was performed by limiting dilution as described 
previously. To test specificity of the clones, T-cells were 
analyzed by means of proliferation, with 250 μg/ml SMX. 
The specific TCC were expanded further by PHA- 
stimulation (1 µg/mL; LaboratoiresEurobio, Cortaboeuf- 
Cedex B, France) in combination with allogeneic, irradi- 
ated PBMCs every 14 days. IL-2 was added after 24 
hours to a concentration of 100 IU final volume, and then 
every 48 hours for 14 days. Both TCC required interac- 
tion with HLA and H13 required autologous APC like 
EBV-B-LCL and did not react to addition of allogeneic 
APC. TCC 1.3 was also stimulated weakly without add- 
ing APC in prior studies, and robustly with the addition 
of non-autologous APC, or HLA-DR-B1*1001 transfec- 
tants.  
4.2. DNA Sequence Alignments 
DNA sequences obtained from sequencing of the reac- 
tive clones were translated using DNA to Protein from 
EMBL translation tool (http://www.ebi.ac.uk/Tools/st/). 
These were then used to obtain the IMGT  
(http://www.imgt.org) nomenclature used by the NIH 
blastp protein sequence searching  
(http://blast.ncbi.nlm.nih.gov) using the IMGT database 
as a template. Further sequence alignments were made 
with all respective clone sequences for the α and β do- 
mains of each sequenced TCR using clustalW multiple 
sequence alignment.  
4.3. Proliferation Assays 
Briefly, 25,000 TCC and 30,000 irradiated PBMCs or 
EBV-B-LCL were incubated together per well with 250 
ug/ml of the indicated compounds, medium alone (CM) 
or PHA (1 ug/ml). 3H-thymidine was added after 48 to 
max 72 hours for exactly 12 hrs and proliferation meas- 
ured via scintillation counting (Top Count, Perkin Elmer). 
Averages of at least three and up to six runs for each ex- 
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perimental condition were collected and all means along 
with statistical differences were calculated. The SA com- 
pounds are listed in Figure 1 and are all obtained from 
Sigma-Aldrich. None of the chemicals showed a toxic 
effect if used <350 μg/ml.  
To test for inhibition of proliferation, the total of two 
compounds, SMX and competitor, were added at the 
same time, with a standard proliferation assay as above. 
All compounds tested in proliferation assays were also 
used in the competition assays. Both compounds together 
were not exceeding 250 μg/ml in total. The range of 
competitive testing was 8:1 - 1:8 (molar ratios). The av- 
erages of at least three independent runs were plotted per 
molar ratio across seven different ratios within the stated 
range, for each point plotted. 
4.4. Calcium Influx Assay 
TCC were incubated for 10 minutes, and spun down 
twice in RPMI w/o Phenol red and then incubated with 2 
μg/ml Fluo-4 AM (Invitrogen, Carlsbad, CA) in RPMI 
w/o Phenol red (Sigma Chemicals Co, Buchs, Switzer- 
land) at 37˚C for 30 min. After incubation, cells were 
washed twice with and resuspended in RPMI w/o Phenol 
red. Cells were plated in half-area clear bottom 96 well 
plates (Corning, LifeSciences, CA, USA) at 1 × 105 cells 
per well (5 × 104 TCC and 5 × 104 irradiated APC or 
EBV) spun for 1 minute at 1500 RPM’s, and further in- 
cubated for 20 min at 37˚C in dark to allow cells to 
equilibrate and uniformly cover the plate surface. Meas- 
urement was performed on a Synergy-4 instrument 
(BioTek Instruments Inc., Highland Park, VT, USA) at 
37˚C with an excitation band of 485/20 nm and fluores- 
cence was measured at 528/20 nm. Baseline signal (F0) 
was recorded during 5 min before the addition of antigen 
solutions and subsequent fluorescence measurements 
were performed for 60 min. PHA stimulation (1 ug/ml 
final well concentration) or ionomycine at 1 ug/ml 
served as positive control. The results are shown as nor- 
malized fluorescence (F/F0)-1. Averages of at least three 
independent runs for each compound were tested per T 
cell clone used with similar results.  
In competition assays, the final combined concentra- 
tions of each competitor and SMX were 250 ug/ml to 
avoid toxicity, at a 1 to 1 ratio. To reduce or eliminate 
variation observed without pre-incubation in calculated 
inhibition, the competing compounds were added with a 
multi-pipette at the start of the calcium reading, and 
SMX added 5 minutes later.  
4.5. Flow Cytometry 
All fluorescent conjugated or unlabeled monoclonal 
antibodies were purchased from BD (Becton, Dickinson 
and Company. NJ, USA) or Biolegend (San Diego, CA, 
USA). For all standard staining, cells were plated in V 
bottom, 96 well plates at 200 K TCC, or 200 K TCC and 
200 K PBMC as indicated. Cells were dyed for 30 min- 
utes at 4˚C in dark, and washed 3 times all on ice with 
chilled PBS before reading. All data points are at least 3 
readings from independent wells, on 1 - 2 separate days, 
using a BD FACSCantoTM. They were analyzed using 
FACS DIVA software. 
In CD107a expression up-regulation kinetic experi- 
ments, cells were plated at 200 K TCC and 200 K PBMC 
per well in normal RPMI supplemented with heat inacti- 
vated 10% FCS. Either the indicated compound, PHA 1 
µg/mL or nothing as a negative control were added [38]. 
Competition of CD107a upregulation by STH was evalu- 
ated with the final concentration of SMX/STH at 125 
ug/ml each. SMX at 125 ug/ml run in parallel was used 
as a control. For all, at least 3 independent reads were 
conducted per time step across 3 different experiments. 
Means of these were then graphed, with standard devia- 
tion represented by error bars. 
4.6. Model Generation 
All protein models were generated using automated 
model building via Swiss-modeller web site  
(http://swissmodel.expasy.org/) [39]. In addition to this, 
models were analyzed using O molecular software [40], 
and further energy minimized using Gromacs, gro- 
mos53a6 force field as necessary to generate the final 
starting structures [41]. For TCRs, the DNA sequences of 
each TCR α and β domain from 8 separate SMX reactive 
clones were used against the highest resolution TCR X 
ray structures found in the PDB database, ranging from 
1.5 to 2.6 Å based on overall amino acid homology 
(PDB codes 1KGC, 1FYT, 1MI5). The generated TCR α 
and β subunits were then aligned in O against the PDB 
1FYT using the MHCII-peptide in the structure as well, 
and further energy minimized in water solevent at 300 K 
until all amino acids fitted a favorable, non-sterically 
inhibited conformation.  
As controls for docking, random poly alanine TCR α 
and β sequences or TCR from a T-cell non-reactive to 
SMX, were generated as above. A second control, we 
used a single TCR α and β from an M. musculis found in 
Uniprot A2NTU7 and Q7TND8, with models generated 
as described. Sequences are shown in supplemental Table 
1 for all reactive clones used to generate initial models. 
All were aligned to the closest matching PDB listed 
above, and energy minimized to eliminate errors from 
alignment in bond lengths or angles. 
Small molecules used in all models, Docking or Mo- 
lecular Dynamics were generated using simple sketch 
and conversion software. In short, the compound struc- 
ture was drawn into ACDlabsChemsketch (Advanced 
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Chemistry Development, Toronto, Ontario, Canada) to 
generate a MDL mol file. These files were then con- 
verted to PDB files with 3D coordinates using OpenBa- 
bel (GNU public license) freeware. As these were small 
molecules, energy minimization prior to using them in 
Docking runs was conducted using simple Chimera 
Software on a PC (UCSF Chimera package from the 
Resource for Biocomputing, Visualization, and Infor- 
matics at the University of California, San Francisco). 
4.7. Docking 
All docking was performed using AutoDock or Auto-
DockVina, used as cross comparisons [42,43]. The later 
software is an optimized version of AutoDock for paral- 
lel processor execution. In all Docking runs, at least 6 
rigid and 6 flexible docking runs were conducted for the 
final analysis. Each run constitutes 10 individual dock- 
ings of each compound used. An initial approach was to 
conduct Docking runs using a spars matrix approach 
encompassing the lower 2/3 of the TCR, and then limit- 
ing runs to regions of the TCR where clustering was ob- 
served. Clustering included 3 or more docked conforma- 
tions in the same region or area within 3 - 4 Å of each 
other from at least 3 sparse matrix runs. These limiting 
runs were then further refined to determined sites show- 
ing clear affinities, and at least 6 limited runs were con- 
ducted. For flexible docking, amino acids in the CDR3 or 
CDR2 loops were allowed to move freely, including back- 
bone flexibility as allowed by AutoDock or AutoDock- 
Vina. For this later, at least 6 additional flexible docking 
runs were conducted. For each TCR model, the com- 
pound library containing all SA was screened against the 
finalized sites of interest. A cutoff for positive versus 
negative docked conformations for all molecules was 
generated for this work alone. The cutoff is based on 
underestimation of full hydrogen bonding energies, and 
takes into account only an arbitrary mean based on 
docking output scores, total hydrogen bonds along with 
initial visual inspection. The resulting scoring cutoff is 
6.5 kCal/mol +/− 0.2, which corresponds to at least 5 
hydrogen bonds [42,44]. 
4.8. Model Analysis 
All final docked ligand models, or model comparisons 
were analyzed using multiple software to check for va- 
lidity. Software used including Pymol ((Schrodinger, 
LLC (2010) The PyMOL Molecular Graphics System, 
Version 1.3r1)), Gromacs and AutoDock Tools, all of 
which have internal analysis tools to measure atomic 
distances and energies produced from Docking software, 
and internal hydrogen bonding or salt bridging based on 
distances and angles [45]. Models were also inspected 
visually using Pymol [45]. Surfaces based on atomic 
radius’s were also generated in Pymol based on AMBER 
internal tables of atomic radius for both docked small 
molecules and the respective TCR, and inspected visually. 
All figures of protein models were generated with a 
freeware Pymol utility rendering script along with the 
Pymol graphics system. 
4.9. Statistical Analysis 
Statistics were performed using qtiplot (Copyright © 
2004-2011 Ion Vasilief and Stephen Besch). Briefly, all 
proliferation, proliferation inhibition and FACS data 
were fed into the software using spreadsheets, and stan- 
dard error, means and standard deviations plotted for 
individual points in all graphs. One way ANOVA was 
performed on plotted data, and significant differences 
scored as <0.05 >0.001, *, or <0.001, ** for respective 
calculated P values. 
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SMX: sulfamethoxazole, SA: sulfanilamides, p-i concept: 
pharmacological interaction concept, TCC: T cell clones, 
TCR: T cell receptor for antigen, MHC: major histo- 
compatibility complex, pMHC: peptide-MHC, CDR: 
complementary determining region 
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(A) 
 
(B) 
Figure S1. Sequences of TCR reactive to SMX used in Modeling Shown are the sequences 
obtained from varied TCC found to be reactive to SMX in previous studies. All TCC were 
isolated from the same patient, showing exanthema/malaise to SMX. Clone names to left cor-
respond to the same TCC TCR in A) TCR variable α and B) TCR variable β. 
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(A)                                     (B)                                      (C) 
 
(D)                                     (E)                                      (F) 
 
(G)                                     (H)                                      (I) 
Figure S2. Proliferation Inhibition curves, other 9 SA Inhibition of SMX induced proliferation for remaining SA. Molar ratios are SA 
to SMX respectively. Names of SA are indicated in chart. Bars represent standard deviation, inclusive of all data from 3 triplicates 
each done in triplicate, representing 9 data points per tested concentration. Most compounds show maximum inhibition between a 
molar excess of 3 to 4 SA to SMX. 
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(A)                                                            (B) 
 
(C) 
Figure S3. Other SA Ca2++ influx (A) Clone 1.3 other 6 SA tested in Ca2++. Shown is a respective SMP Ca2++ influx, with re- 
sponse scaled to Figure 3 for comparison. All others gave no influx. (B) Clone H13 other 6 SA. SMX is shown as a control, only 
SDZ gave a response from the set of SA shown. (C) Zoom of (B) to show more precise influx scale. 
 
 
Figure S4. Ca2++ Inhibition of TCC 1.3, remaining 6 SA Inhibition of SMX induced Ca2++ influx for 
remaining 6 SA of TCC 1.3. All inhibitions were are conducted at a molar ratio of 1:1 SA to SMX. 
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Figure S5. Overlay of all SA in CDR3α of Clone 1.3 
Overlay of all SA docked into the CDR3α loop of clone 
1.3. Top of figure, TCR, bottom MHC-peptide groove. 
Each was docked, then energy minimized until no change 
in energy was observed using GROMACS. The NH2 of 
the terminal SA core shows no movement due to the strong 
interaction with CDR1β TYR 31, while R groups show a 
wide degree of displacement. SMP is overlaid in reversed 
docked conformations, to illustrate orientation, where the 
TYR 31 is displaced by the CH3 group. 
 
 
Figure S6. Dehydrated and Hydrated SA Comparisons (A) Dehydrated, green, and hydrated 
SMX, pink docked into the CDR3α loop of clone 1.3. The hydrogen is drawn into SMX, nor- 
mally not represented in figures to show the offset caused by removal. The molecule rotates, 
allowing the N of the neck-R group to form a hydrogen bond with backbone H between posi- 
tion 95 and 96. An additional hydrogen bond deficit is made through ASN 91, which forms a 
bond to the displaced o of the SO2. (B) Dehydrated, gray and non-dehydrated SDM, aqua. A 
change in the S-N-R group angle from 110˚ to 127˚ allows the SA core to be properly placed 
in the binding pocket. Amino acids of the CDR2β loop of H13 are labeled. 
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